The Obesity Treatment Desert

The crisis in four numbers

The United States spends more on obesity and diabetes than the GDP of all but eleven countries. Yet for the 106 million adults living with obesity, getting treatment depends less on medical need than on geography.

The Obesity Treatment Desert Index — mapped above — scores all 50 states and Washington, D.C. on a composite scale measuring the gap between disease burden and treatment access. The pattern is stark: the states where obesity and diabetes rates are highest are the same states with the fewest specialists, the least insurance coverage for weight loss medications, and the lowest rates of surgical intervention.

The GLP-1 promise — and its limits

GLP-1 receptor agonists like Ozempic, Wegovy, and Zepbound have transformed the public conversation about obesity. They work. But the data on long-term use tells a different story.

An analysis of 16.5 million covered lives by Prime Therapeutics (June 2025) found that only 8.1% of patients prescribed GLP-1 medications for obesity remained on therapy at three years. That means nearly 92 out of every 100 patients who start these drugs will stop taking them.

The reasons are well-documented. A JAMA Network Open study of 125,474 patients (January 2025) found that side effects account for 28% of all GLP-1 discontinuations, followed by cost at 13%. Nausea, vomiting, and gastrointestinal distress are the most commonly reported adverse effects. And the consequences of stopping are severe: the STEP 1 extension trial showed that patients who discontinued semaglutide regained approximately 67% of their lost weight — an average of roughly 10 kg — within 12 to 18 months.

Oral GLP-1 formulations, launched in early 2026, address the injection barrier. But they do not solve the fundamental problems: chronic dependency, persistent side effects, high cost, and weight regain upon cessation. These drugs manage obesity. They do not resolve it.

The specialist gap

Even when patients can afford treatment and tolerate the side effects, many simply cannot access a specialist. Approximately 70% of U.S. counties have zero practicing endocrinologists, according to a December 2024 analysis by GoodRx and HealthLink Dimensions. That affects roughly 50 million Americans.

The shortage is not distributed equally. States in the Southeast and Appalachia — where obesity and diabetes rates are highest — have the fewest specialists per capita. West Virginia, the state with the highest obesity rate in the nation (41.4%), has just 2.4 endocrinologists per 100,000 residents. Washington, D.C. has 9.6.

Bariatric surgery, the most clinically effective intervention for severe obesity, reaches an even smaller fraction of those who need it. Despite clinical guidelines recommending surgery for patients with BMI ≥ 35, only approximately 1% of clinically eligible patients nationwide receive the procedure, according to the American Society for Metabolic and Bariatric Surgery (2025). State utilization rates range from 2.1% in Vermont to 10.4% in New Jersey.

The Medicaid coverage cliff

For the 90 million Americans covered by Medicaid, access to GLP-1 therapy for obesity is largely determined by which state they live in. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for weight loss — down from 16 in mid-2025, after California, New Hampshire, Pennsylvania, and South Carolina eliminated coverage due to cost pressures.

The cost calculus is straightforward: GLP-1 therapy for obesity costs Medicaid programs approximately $2,940 per patient per year at the Medicare negotiated rate, with no defined end date. For states already facing budget constraints, covering an open-ended prescription for a condition affecting 30-40% of their adult population is financially untenable. The result is a coverage cliff that tracks geography almost perfectly — the poorest states with the highest disease burden are the least able to fund pharmacotherapy.

The diabetes remission gap

Perhaps the most significant finding from the treatment desert data is its implication for Type 2 diabetes. More than 37 million Americans have T2D, at an annual cost exceeding $412 billion (ADA, 2022). The DiRECT trial, published in The Lancet in 2018, demonstrated that 46% of Type 2 diabetes patients achieved complete remission through intensive dietary intervention — total diet replacement delivering nutrients directly to the gut — without drugs or surgery.

Yet adoption of dietary remission protocols remains extremely low. Approximately 8 million Americans with T2D meet the clinical profile for dietary remission — disease duration under six years, BMI 27–45, not insulin-dependent — according to the CDC National Diabetes Statistics Report (January 2026). Most will never be offered this option.

No GLP-1 receptor agonist — injectable or oral — achieves Type 2 diabetes remission. These drugs reduce HbA1c and body weight, but patients must continue taking them indefinitely to maintain the effect. Bariatric surgery achieves remission in approximately 60% of cases, but requires general anesthesia, carries surgical risks, and costs $17,000–$26,000.

What the map reveals

The five worst-scoring states on the Treatment Desert Index are all in the Southeast: West Virginia, Mississippi, Louisiana, Alabama, and Arkansas. These states share a common profile: adult obesity rates exceeding 38%, diabetes rates above 15%, endocrinologist density below the national average, no Medicaid GLP-1 coverage for obesity, and bariatric surgery utilization among the lowest in the nation.

The five best-scoring states — Colorado, Massachusetts, Washington D.C., New Jersey, and Hawaii — have obesity rates below 28%, higher specialist density, and in several cases, active Medicaid GLP-1 coverage.

The gap between these two groups is not marginal. It is a 3× difference in specialist access, a 15-percentage-point spread in obesity prevalence, and in many cases a binary difference in whether the state will pay for the most widely prescribed obesity treatment in history.

The path forward

The treatment desert will not be closed by a single intervention. GLP-1 drugs helped millions of patients in the short term, but the 92% discontinuation rate proves that chronic pharmacotherapy alone is not a durable solution at the population level. Bariatric surgery is effective but inaccessible. Medicaid coverage is contracting, not expanding.

This map is a starting point for that conversation. Use the State Report Card tool above to generate a citable data summary for any state — ready for grant applications, policy briefs, presentations, or articles.